BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld
Home
» Pharmacyclics: New Phase III Sharpens Cancer Drug’s Focus
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Pharmacyclics: New Phase III Sharpens Cancer Drug’s Focus
April 17, 2002
By
Randy Osborne
No Comments
Pharmacyclics Inc. is planning a new Phase III trial of its cancer cell disrupter, Xcytrin, in the sector of patients for whom the drug seems to do the most good those with lung cancer that has metastasized to the brain. (BioWorld Today)
BioWorld